Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor.
Schmidt
M L
ML
Division of Pediatric Hematology/Oncology, Children's Memorial Hospital, Northwestern University, Chicago, Illinois.
Smith
H E
HE
Gamerman
S
S
DiMichele
D
D
Glazer
S
S
Scott
J P
JP
D002648:Child; D003161:Compartment Syndromes / Q000628:therapy; D004334:Drug Administration Schedule; D005164:Factor IX / Q000276:immunology; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D002836:Hemophilia B / Q000276:immunology / Q000628:therapy*; D006470:Hemorrhage / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D007074:Immunoglobulin G; D011994:Recombinant Proteins; D005164:Factor IX; D015942:Factor VIIa